Clinical Trial Detail

NCT ID NCT00764972
Title Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer
Recruitment Unknown status
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors McGill University
Indications

Her2-receptor negative breast cancer

Therapies

Sorafenib + Vinorelbine

Age Groups: adult

Additional content available in CKB BOOST